Prefilled Syringes Market to Hit $22.8 Billion by 2029, Driven by Innovation and Demand Surge [Yahoo! Finance]
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones [Yahoo! Finance]
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Design Therapeutics, Inc. (NASDAQ: DSGN) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $12.00 price target on the stock, up previously from $6.00.
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference